Related Experiment Videos
Bivalirudin: a new generation antithrombotic drug
1Istituto Chimica e Chimica Clinica, Università Cattolica del Sacro Cuore, Largo Francesco Vito 1, 00168 Rome, Italy. r.scatena@uniserv.ccr.rm.cnr.it
Expert Opinion on Investigational Drugs
|November 4, 2000
Summary
Bivalirudin is a novel anticoagulant peptide that directly inhibits thrombin, offering a potential alternative to heparin for cardiovascular diseases like unstable angina and myocardial infarction.
Area of Science:
- Pharmacology
- Biochemistry
- Cardiovascular Medicine
Background:
- Bivalirudin is a synthetic peptide anticoagulant.
- It is designed based on hirudin, a natural anticoagulant.
- Bivalirudin targets thrombin, a key factor in blood clot formation.
Purpose of the Study:
- To introduce bivalirudin as a new class of anticoagulant.
- To highlight its mechanism of action.
- To suggest its potential applications in cardiovascular disease management.
Main Methods:
- Structural studies of hirudin.
- Rational drug design of a 20 amino acid peptide.
- Assessment of thrombin inhibition and binding affinity.
Main Results:
- Bivalirudin demonstrates high binding affinity and specificity for thrombin.
- It directly inhibits thrombin activity.
- It acts independently of other clotting factors.
Conclusions:
- Bivalirudin represents a novel class of direct thrombin inhibitors.
- It offers a potential alternative to heparin.
- Potential applications include unstable angina, myocardial infarction, and percutaneous transluminal coronary angioplasty.